1. Home
  2. VS vs BIVI Comparison

VS vs BIVI Comparison

Compare VS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.35

Market Cap

9.3M

Sector

Technology

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.39

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VS
BIVI
Founded
2013
2013
Country
United States
United States
Employees
5
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
10.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VS
BIVI
Price
$1.35
$1.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.3K
212.1K
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$1.06
52 Week High
$2.72
$7.17

Technical Indicators

Market Signals
Indicator
VS
BIVI
Relative Strength Index (RSI) 45.18 40.46
Support Level $1.17 $1.19
Resistance Level $1.78 $1.40
Average True Range (ATR) 0.13 0.20
MACD -0.02 -0.07
Stochastic Oscillator 8.93 12.86

Price Performance

Historical Comparison
VS
BIVI

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: